Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21959838 | 0.90 | KDM4E (0.40) | KDM4EALDH1A1MAPK1CHRM1LMNA | |
| SCHEMBL21875405 | 0.86 | MAPT (0.40) | KDM4EALDH1A1MAPK1CHRM1KLKB1 | |
| SCHEMBL21875422 | 0.79 | CHRM1 (0.59) | CHRM1 | |
| SCHEMBL21875441 | 0.74 | PPARG (0.40) | KDM4EALDH1A1MAPK1CHRM1LMNA | |
| Lithium Ion SCHEMBL21878483 | 0.73 | CHRM1 (0.46) | KDM4EALDH1A1MAPK1CHRM1LMNA | |
| SCHEMBL21875407 | 0.71 | MAPT (0.41) | CHRM1KLKB1KLK1 | |
| Lithium Ion SCHEMBL21878456 | 0.66 | CHRM1 (0.43) | CHRM1MPO | |
| SCHEMBL29169982 | 0.65 | SYK (0.43) | KDM4EALDH1A1MAPK1CHRM1LMNA | |
| SCHEMBL28131929 | 0.65 | HTT (0.58) | KDM4EALDH1A1MAPK1LMNAKLKB1 | |
| SCHEMBL21929477 | 0.64 | CHRM1 (0.47) | KDM4EALDH1A1MAPK1CHRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | KDM4E 1530/4885ALDH1A1 3782/4885MAPK1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.